top of page
OPHELIA
EFFECTIVENESS OF OLAPARIB PLUS TRASTUZUMAB IN HER2-POSITIVE BRCA-MUTATED ADVANCED BREAST CANCER PATIENTS (THE OPHELIA STUDY)
CLINICAL TRIAL DETAILS
THE OPHELIA STUDY IS A MULTICENTER, OPEN-LABEL, SINGLE-ARM, TWO COHORTS, SIMON’S TWO-STAGE MINIMAX DESIGN, PHASE II CLINICAL TRIAL. THE PRIMARY OBJECTIVE OF THIS TRIAL IS TO ASSESS THE EFFICACY – AS DETERMINED BY THE OVERALL RESPONSE RATE (ORR) AND PROGRESSION-FREE SURVIVAL (PFS) BASED ON RECIST V.1.1 – OF OLAPARIB IN COMBINATION WITH TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE, GERMINAL BRCA1/2 MUTATED ABC.
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
PRESS RELEASE
SCIENTIFIC IMPACT
ESMO 2019 poster: https://39f1664e-7766-40bf-9b5a-e3575d54bba6.usrfiles.com/ugd/39f166_49368b0a907242a3b9407f2f24a71c42.pdf | SABCS 2022 poster: https://d9ec78c0-6610-4e58-b628-a2262f2019e2.usrfiles.com/ugd/d9ec78_58e6ed5693dc44a4b0ede624fd6214db.pdf
BLOG ARTICLES RELATED
PHERGAIN SITES
Hospital Arnau de Vilanova de Valencia (Spain) | Complejo Hospitalario de Jaén (Spain) | Hospital Universitario Virgen del Rocío (Spain) | Onkologikoa (Spain) | Hospital Clínico San Carlos (Spain) | Hospital Son Llatzer (Spain) | Hospital Universitario Virgen de la Victoria (Spain) | Hospital Universitari Son Espases (Spain) | Hospital Universitari Vall D'Hebron (Spain) | Hospital Universitario Arnau de Vilanova de Lleida (Spain) | Complejo Hospitalario Universitario de Santiago (CHUS) (Spain) | Hospital San Pedro de Alcántara (Spain) | Complejo Asistencial de Ávila (Spain) | Hospital Clínico Universitario de Valencia (Spain) | Hospital Universitario Reina Sofía (Spain) | Hospital Universitario Ramón y Cajal (Spain) | Hospital Universitario La Paz (Spain)
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page